The AstraZeneca PLC ADR AZN slid 0.68% to $66.94 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.66% to 19,902.84 ...

We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...

An AstraZeneca Pharmaceuticals PLC subsidiary faces a lawsuit from a former director who said she was subjected to sexist treatment from male colleagues and retaliation after filing a report with HR ...

The AstraZeneca share price is down almost 20% since September! What’s behind this drop, and where do analysts think the ...

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

AstraZeneca on Wednesday named Iskra Reic as its new international executive vice president (EVP), taking over from Leon Wang ...

Updated results from the OlympiA Phase 3 trial showed AstraZeneca (AZN) and Merck’s (MRK) Lynparza demonstrated sustained, clinically ...

Shares of AstraZeneca PLC AZN inched up 0.45% to £107.02 Monday, on what proved to be an all-around favorable trading session ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...